B2B pharma and life sciences commercial market research: reaching market access, medical affairs, and commercial leaders
Pharma commercial research reaches market access, HEOR, medical affairs, and brand leaders, not patients or clinicians. This guide covers who you need to reach, the methods that work, and how to source verified commercial professionals quickly.
B2B pharma and life sciences commercial market research is research conducted with the commercial side of the industry, market access, health economics and outcomes research, medical affairs, pricing and reimbursement, and brand and commercial leaders, to inform launch strategy, payer engagement, pricing, and positioning. It is deliberately distinct from clinical and patient research: the audiences are the professionals who bring a therapy to market and secure access, not the clinicians who prescribe or the patients who use it. This guide covers why commercial pharma research is hard, who you actually need to reach, the methods that work, and how to source real professionals fast enough to hit a launch or pricing deadline.
Someone searching for a pharma commercial market research partner usually has a launch, a pricing decision, or a payer strategy riding on what real market access and medical affairs leaders think, and has discovered that reaching a global market access lead in oncology is nothing like reaching a general healthcare panel. The constraint is almost always sourcing and verifying the right professionals. If your need is clinical or clinician-facing instead, that is a different discipline, and our guide to B2B healthcare market research with verified clinicians, physicians, and HCPs is the right starting point.
Why pharma commercial research is its own discipline
Three forces make commercial pharma research distinct, and conflating it with clinical research is the most common and expensive mistake.
First, the audience is commercial and medical-affairs professionals, not care providers. A pricing decision does not need physicians in general. It needs the market access lead, the HEOR specialist, or the payer who decides what gets reimbursed and at what price. A launch decision needs brand and commercial leaders. A scientific-communication decision needs medical affairs and medical science liaisons. These functions see a therapy completely differently from the prescriber, and treating them as interchangeable produces strategy built on the wrong lens.
Second, the functions are narrow and specialized by therapeutic area. A market access lead in oncology is not interchangeable with one in rare disease, and a brand manager sees nothing of the payer negotiation that a reimbursement specialist lives in. Standards for how pharma market research is conducted are set by bodies like the European Pharmaceutical Market Research Association and, for health economics evidence, by ISPOR, while industry context comes from associations such as PhRMA and EFPIA. Getting a near-miss function produces confident, specific, and wrong data.
Third, pharma is heavily regulated on what can be said and studied. Promotional and scientific-exchange rules, overseen by regulators such as the Food and Drug Administration and the European Medicines Agency, shape how products and evidence can be discussed, and adverse-event reporting obligations attach to any professional conversation about a therapy. Researchers have to design around these constraints, and a fabricated or near-miss respondent is not just misleading here, it is a compliance risk. Industry outlooks from Deloitte and McKinsey show how much launch and access strategy now rides on getting the commercial practitioner view right.
The usual approach, buy a healthcare panel and field a survey, breaks down here. Generic panels cannot reliably deliver a verified global market access lead in oncology, and unverified panels will hand you someone pretending to be one.
Who you need to reach
Pharma commercial research is not one audience. The right participant depends entirely on the decision, and mixing functions produces results that look rigorous and mislead badly. None of these audiences are patients or treating clinicians.
Market access and HEOR leaders own the strategy for securing reimbursement and demonstrating value to payers. They are the right audience for pricing, value-proposition, and evidence-strategy decisions, and they evaluate on payer logic and health-economic defensibility.
Pricing and reimbursement specialists own the negotiation with payers and health technology assessment bodies. They matter for any pricing or access decision, where the real constraint is what a payer will fund, not what a brand team hopes to charge.
Medical affairs and medical science liaisons own scientific exchange and evidence communication. For scientific-platform, publication, and field-medical decisions these are both the practitioners and the internal buyers of research.
Brand and commercial leaders are brand managers, marketing directors, and commercial heads who own launch and positioning. They matter for message testing, competitive positioning, and launch readiness, and reaching this seniority follows the same logic as our guide to recruiting senior B2B decision-makers for research.
The table below maps common decisions to the professionals you need.
| Decision | Primary audience | Secondary audience | Sourcing difficulty |
|---|---|---|---|
| Pricing or reimbursement strategy | Market access, HEOR, pricing leads | Payers | Very high: narrow function plus therapeutic area |
| Launch positioning or message test | Brand and commercial leaders | Medical affairs | High: seniority plus market |
| Evidence or scientific platform | Medical affairs, MSLs | HEOR | High: function plus therapeutic area |
| Payer landscape research | Payers, access leads | Pricing specialists | Very high: tiny senior population |
| Competitive or win-loss research | Commercial leaders, access leads | Field teams | High: role verification plus market |
Why verification decides the study
In pharma commercial research, verification is the difference between a finding you can take to a launch committee and one that quietly misdirects an access strategy, and it carries compliance weight that most verticals do not. Because the functions are narrow and specialized, the single most important design choice is how you confirm each participant is who they claim to be.
Credible verification checks a participant’s work profile, employer, function, therapeutic area, and seniority against trusted professional data before they enter the study, rather than trusting a self-reported screener. A near-miss function, a brand manager answering as a market access lead, produces confident and wrong data, which is worse than no data because teams act on it. This is the discipline that separates reliable from unreliable sourcing, and it is the same reasoning behind our companion guides to B2B insurance and insurtech market research with underwriters and claims leaders and B2B telecom market research with network, IT, and procurement decision-makers.
Methods that work for pharma commercial research
The method follows the decision. Four approaches carry most commercial pharma studies.
Expert interviews are the backbone of early access and launch research. Ten to twenty structured conversations with the right market access or medical affairs leaders will surface the payer logic, the evidence gaps, and the positioning a therapy has to win on, long before a survey can. The craft of sourcing, screening, and running these sits in our guide to B2B market research expert interview methods, and the consultative, high-stakes style mirrors our guide to expert interviews for investment and consulting research.
Payer and access research is often smaller and more senior, because the payer population is tiny and the conversations are confidential. A handful of verified payers can reshape a pricing model, which makes verification and discretion matter more than raw sample size.
Message and value-proposition testing validates whether a launch narrative survives contact with the commercial and medical-affairs professionals who will carry it, and whether the value story holds up against payer logic.
Opportunity sizing and segmentation surveys quantify demand and attitudes across therapeutic areas, markets, and functions. These typically need 75 to 200 verified respondents per segment and depend entirely on whether the sample is genuinely who it claims to be. Across all four methods, the standard for how professionals are recruited, incentivized, and quoted should follow a recognized research code such as the one from ESOMAR, alongside the pharma-specific guidance that governs adverse-event handling.
Sample sizes and timelines
For qualitative work, plan 10 to 20 participants per function or market to reach saturation, and expect payer research to run smaller. For quantitative work, plan 75 to 200 verified respondents per key segment, and more when you compare therapeutic areas or geographies. The target number is rarely the constraint. The constraint is how fast you can source verified commercial and medical-affairs professionals, who are scarce and slow to reach.
With an always-on verified network, a focused pharma commercial study runs in two to five weeks: roughly one to two weeks of fielding plus analysis. Teams that rely on specialist agencies often spend that entire window just finding people, which is why our guide to running fast B2B market research in days treats sourcing speed as the real lever.
A practical workflow
A reliable pharma commercial study follows a repeatable sequence. First, define the decision and the exact function, therapeutic area, and market that can inform it, and confirm it is a commercial question rather than a clinical one. Second, write a screener that qualifies on verifiable function and therapeutic-area attributes, not self-reported titles. Third, verify every participant against professional data before they enter. Fourth, build adverse-event handling into the protocol from the start. Fifth, analyze by function and market, never pooling market access with brand or oncology with rare disease.
The teams that get commercial pharma research right treat it as a sourcing, verification, and compliance problem first and a methodology problem second. The method is well understood. Reaching a verified market access lead or a payer in the right therapeutic area on a deadline is the hard part.
Frequently asked questions
What is pharma and life sciences commercial market research?
It is research conducted with the commercial side of pharma and life sciences, market access, health economics and outcomes research, medical affairs, pricing and reimbursement, and brand and commercial leaders, rather than with patients or clinicians, to inform launch strategy, pricing, payer engagement, and positioning. It spans demand and payer landscape research, message and value-proposition testing, and win-loss and competitive research, all with verified professionals in the exact function and seniority the study requires.
How is commercial pharma research different from clinical or patient research?
Commercial research reaches the professionals who bring a therapy to market and secure access and reimbursement, not the clinicians who prescribe or the patients who use it. The audiences are market access and HEOR leaders, pricing and reimbursement teams, medical affairs and medical science liaisons, and brand and commercial leaders, often alongside payers. Clinical and patient recruitment is a separate discipline with its own ethics and regulatory requirements, covered in our guide to healthcare research with clinicians and HCPs.
Who do you need to reach for pharma commercial research?
It depends on the decision. Pricing and reimbursement decisions need market access, HEOR, and pricing leaders, and often payers. Launch and positioning decisions need brand, marketing, and commercial leaders. Scientific communication and evidence decisions need medical affairs and medical science liaisons. The constant is that every participant must be a verified professional in the exact commercial or medical-affairs function and seniority the study targets, not a general healthcare respondent.
How do you verify that a research participant is a real pharma commercial professional?
Credible verification checks identity against professional data rather than trusting a self-reported screener. That means confirming a participant’s work profile, employer, function, therapeutic area, and seniority against trusted sources before they enter the study. In pharma this matters because the functions are specific, a market access lead is not interchangeable with a brand manager, and promotional and compliance rules make a fabricated or near-miss respondent both misleading and risky.
How many pharma commercial professionals do you need for a study?
Qualitative interviews usually run 10 to 20 participants per function or market to reach thematic saturation, and payer research is often smaller because the population is tiny and senior. Quantitative surveys that size opportunity or test messaging typically need 75 to 200 verified respondents per key segment, more when you compare therapeutic areas or geographies. The binding constraint is rarely the target number but how fast you can source verified commercial and medical-affairs professionals.
How fast can pharma commercial research be done with verified professionals?
With an always-on verified network, a focused pharma commercial study runs in two to five weeks: roughly one to two weeks of interviews or survey fielding plus analysis. The slow variable is sourcing credentialed market access, medical affairs, and commercial leaders in the right therapeutic area and market, so a network that can match and verify them on demand compresses the timeline more than any other single change.
Source verified pharma commercial professionals with CleverX
CleverX gives pharma and life sciences teams direct access to a network of more than 8 million verified B2B and B2C professionals across 150+ countries, including market access, HEOR, pricing and reimbursement, medical affairs, medical science liaison, and brand and commercial leaders whose function, therapeutic area, and seniority are checked against professional data before they ever enter a study. That means you reach the exact commercial function your launch or pricing decision depends on, screen out fabricated respondents, and get results in days rather than the weeks a specialist agency would take.